In a long article, eight researchers published in Nature Biotechnology a detailed survey of biotech in China, looking at its current condition and defining initiatives that would improve its growth. The article is part of a larger series of articles that investigate biopharma activity around the globe. While China has supported emerging biotechs with grants and subsidies,  the authors fault China for failing to provide exits for investors. More details...